Understand the source comparison
Cartalax vs Other Gastric Peptides: Research Comparison
Cartalax (Ala-Glu-Asp-Gly) HSP70 upregulation, epithelial cytoprotection Preclinical (animal models) Ulcer index reduction, mucosal thickness Promising in vitro and animal data; human trials insufficient for regulatory approval BPC-157 (pentadecapeptide) Angio
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cartalax (Ala-Glu-Asp-Gly)
- HSP70 upregulation, epithelial cytoprotection
- Preclinical (animal models)
- Ulcer index reduction, mucosal thickness
- Promising in vitro and animal data; human trials insufficient for regulatory approval
- BPC-157 (pentadecapeptide)
- Angiogenesis promotion, VEGF pathway activation
- Preclinical (animal models, some human case reports)
- Tendon healing rate, gastric ulcer closure time
- Broader tissue repair applications than Cartalax; similar evidence limitations
- Thymalin (thymus extract)
- T-cell modulation, immune system support
- Observational human studies (Eastern Europe)
- Immune marker panels, infection recovery time
- Immune-focused mechanism unrelated to gastric tissue repair
- PL (liver hydrolysate peptides)
- Hepatocyte regeneration, detoxification enzyme support
- Preclinical + small controlled trials
- Liver enzyme normalisation, fibrosis markers
- More human data than Cartalax but still outside mainstream regulatory pathways
- Cartalax occupies a narrow research niche. Gastric epithelial protection and repair. If you're comparing peptides for research applications, Thymalin targets immune function, BPC-157 addresses broader soft tissue repair, and Cartalax is specific to gastric mucosa. The evidence quality is similar across all three. Robust preclinical data, sparse human trials. But the mechanisms are distinct. Choosing the right peptide depends on your study's biological target, not on which compound has the most compelling marketing narrative.